Benzinga | Dec 14, 2021 09:09AM EST

Citigroup Downgrades Arena Pharmaceuticals to Neutral, Lowers Price Target to $100

Citigroup analyst Neena Bitritto-Garg downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Buy to Neutral and lowers the price target from $101 to $100.